The Italian subsidiary of Swiss drug maker Roche manufactures all of the company's most successful medications -- hepatitis B and C drug Pegasys, cancer drugs Herceptin and Avastin, and MabThera, for non-Hodgkin lymphoma. Roche S.p.A.'s business is roughly 40% oncology and hematology, 30% specialty care (Pegasys, Neorecormon, Copegus), and 30% primary care (analgesics, antibiotics). Its 700,000-square-foot production facility in Segrate, a town near Milan in northern Italy, produces almost 1,400 tons of medication every year, about 60% of which is exported across Europe.

Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Its pipeline includes clinical and pre-clinical product candidates with mechanisms of action and novel chemical structures. The company's product candidates in clinical development include Azixa (MPC-6827), which is under Phase II clinical trial for the treatment of glioblastoma multiforme and metastatic melanoma; MPC-4326 for HIV-1 infection under Phase IIb clinical trial; and MPC-3100, a Phase I clinical trial product candidate for cancer treatment. Its products in preclinical programs comprise MPI-443803, an orally available, brain penetrant, microtubule destabilizing agent for the treatment of cancer; and MPI-461359, an orally available maturation inhibitor for the treatment of HIV-1 infection, as well as MPI-479605 for the treatment of cancer. The company also offers ProNet, a proprietary database of protein-protein interactions, which encompasses interactions between approximately 10 million protein fragments constructed from various organ tissues, including heart, brain, kidney, liver, breast, and prostate. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.

Par Pharmaceutical Companies, Inc. was founded in 1978 and is based in Woodcliff Lake, New Jersey. Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States. Its principal generic products include Metoprolol succinate ER, Fluticasone, Meclizine Hydrochloride, Cabergoline, Sumatriptan succinate injection, Propranolol HCl ER, amoxicillin products, Dronabinol, Ibuprofen Rx, Megestrol oral suspension, Methimazole, Fluoxetine, Lovastatin, Tramadol HCl and acetaminophen tablets, Ranitidine HCl Syrup, Quinapril, and Cefprozil. The company offers its drugs in the solid oral dosage form, such as tablets, caplets, and two-piece hard-shell capsules, as well as oral suspension products and certain products in the semi-solid form of a cream.It markets its products to wholesalers, drug store chains, supermarket chains, mass merchandisers, distributors, managed health care organizations, mail order accounts, drug distributors, clinics, and government agencies. The company's brand products include Megace ES drugs for the treatment of anorexia, cachexia, or any unexplained significant weight loss in patients with a diagnosis of AIDS; and NanoCrystal Dispersion for megestrol acetate oral suspension. It has a joint venture with Rhodes Technology to research, develop, commercialize, and market pharmaceutical preparations for human therapy; a license and commercialization agreement with Intellipharmaceutics Corp. for the development of Dexmethylphenidate XR; and a development and supply agreement with Cipla Limited for the development of one generic product. The company has a collaboration agreement with Actavis Group for the development of 4 extended release generic products, such as Nifedipine XR, Methylphenidate LA, Zolpidem CR, and Alfuzosin.

Zeltia SA is a Spain-based holding company primarily engaged, through its subsidiaries, in the chemical and pharmaceutical sectors. Its main subsidiaries are: PharmaMar SA, biopharmaceutical company committed to advancing the treatment of cancer; Noscira SA, engaged in the research and development of innovative drugs for diseases of the nervous system; Genomica SAU, specializes in molecular diagnosis; Sylentis SAU, focused on the discovering and developing new therapeutic approaches based on gene silencing techniques; Zelnova SA, which produces and markets cleaning products for household and cetring sectors; and Xylazel SA, producer of paints, varnishes, wood and metal protectors for the industrial sector.

ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California. ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. Its product portfolio includes tecarfarin, an oral anticoagulant in Phase II/III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; budiodarone/ATI-2042, an oral antiarrhythmic agent in Phase II clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat; ATI-7505, an oral prokinetic agent in Phase II clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. The company also involves in the preclinical development of ATI-20,000 and ATI-24,000, which focus on metabolic and gastrointestinal disorders.

AspenBio Pharma, Inc. company was founded in 2000 and is based in Castle Rock, Colorado. AspenBio Pharma, Inc. (AspenBio) is a biotechnology company engaged in the discovery, development, manufacture, and licensing or marketing of products. The Company is primarily focused on advancing towards commercialization its blood-based human diagnostic test, AppyScore to aid in the diagnosis of human appendicitis and several reproduction drugs for use in high value animals. AppyScore is a blood-based test to the aid in diagnosis of appendicitis. AppyScore measures the abundance of MRP 8/14, an inflammation biomarker, which AspenBio has identified to be elevated in acute appendicitis and demonstrates a correlation to the severity of the disease. In December 2008, the Company completed an 800 patient pivotal clinical trial for AppyScore. Products in its pipeline consist of product candidates in various stages of clinical and pre-clinical development.

Insmed Incorporated Company was founded in 1999 and is headquartered in Richmond, Virginia. Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company's primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X.

ADVENTRX Pharmaceuticals, Inc. company was founded in 1995 is based in San Diego, California. ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

Allergy Research Group Inc. offers nutritional supplement products. It offers amino acids, antioxidant formulas, bioenergetics, bioflavonoids, blood sugar, books, brain, cardiovascular, comprehensive formulas, fatty acids, eye, gastric support, glandulars, and hormone products. Allergy Research Group also provides immune support, liver support, martin pall products, metabolic support, microbial balancers, minerals, multiples, musculoskeletal, probiotics, specialty products, vitamin B products, vitamin C products, and vitamin D, E, K products. The company was founded in 1979 and is headquartered in Alameda, California. As of September 9, 2008, Allergy Research Group Inc. operates as a subsidiary of KI NutriCare, Inc.

Novavax, Inc. was founded in 1987 and is headquartered in Rockville, Maryland. Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing vaccines using its virus-like particle platform technology for infectious diseases. It develops vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, and Respiratory Syncytial Virus, as well as Varicella Zoster that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza virus-like-particle-based vaccine candidates and therapeutic vaccine candidates against cancer, as well as adjuvants, biogeneric products, and other diagnostic products for the territory of India. It also has a strategic collaboration Xcellerex Inc. for the production of 2009 H1N1 influenza vaccine.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.